drugset / Trial / NCT06644326
A PK Study of IkT-148009 in Older and Elderly Healthy Subjects
RandomizedSequentialOpen-labelBasic science
Summary
This is a two-part study. Part A consists of two different IkT-148009-201 solid dosage formulations that are being evaluated to determine their steady-state pharmacokinetic profile. Part B is a drug-drug interaction (DDI) study focused on evaluating the impact of a strong CYP3A inhibitor on the preferred dosage determined in part A.
Timeline
- Start
- 2023-06-21
- Primary completion
- 2024-08-17
- Completion
- 2024-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Itraconazole | Small molecule | 200 mg | — |
| Comparator | RISVODETINIB | Small molecule | 50 mg | — |
| Comparator | RISVODETINIB | Small molecule | 100 mg | — |
Indications
No indication recorded.